AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20238247
Drug: Modified-release esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release esomeprazole 60 mg od
Trial: 20238247
Drug: Modified-release esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release esomeprazole 80 mg od
Trial: 20238247
Drug: Modified-release esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release esomeprazole 40 mg od
Trial: 20238247
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation esomeprazole 20 mg bid
Trial: 20238247
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation esomeprazole 40 mg bid
Trial: 7992938
Drug: Fraxiparine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxiparine (0.3 mL, 3,075 anti Xa IU per day, one daily subcutaneous injection)
Trial: 7992938
Drug: Calciparine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calciparine (0.2 mL t.i.d., 15,000 IU per day, one subcutaneous injection)
Trial: 2514323
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (Benzodiazepine antagonist)
Trial: 29170073
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fentanyl (control)
Trial: 25255113
Drug: Vertical scar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertical scar reduction (for reductions less than 500 g)
Trial: 22221076
Drug: telcagepant (280-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant (280-mg tablet/300-mg capsule)
Trial: 20669013
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg three times daily for 3 days)
Trial: 20669013
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 HEMs and PMs
Trial: 20669013
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 EMs
Trial: 17573359
Drug: AutoCapture devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AutoCapture devices with steroid‐eluting epicardial leads
Trial: 16288378
Drug: vCP205 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 vaccine formulation (10(6.08) TCID(50))
Trial: 16288378
Drug: vCP205 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 vaccine formulation (10(6.33) TCID(50))
Trial: 16288378
Drug: vCP205 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 vaccine (both formulations)
Trial: 11843746
Drug: Oxygen at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen at 2 l x min(‐1) by nasal cannulae
Trial: 19496103
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid)
Trial: 11915064
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (10 mL/h)
Trial: 11915064
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (5 mL/h basal rate with 5 mL bolus every 60 minutes)
Trial: 1978475
Drug: Remoxipride CR
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride CR (385 mg daily)
Trial: 1978475
Drug: Haloperidol (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (17 mg daily)
Trial: 31800542
Drug: Crofelemer (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crofelemer (125 mg)
Trial: 28131677
Drug: Routine antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibacterial therapy
Trial: 17699383
Drug: Dependence on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dependence on activity of daily living scale
Trial: 19089782
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days
Trial: 15219887
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days + phytoestrogens (PE) 1500 mg daily for 10 days
Trial: 10798461
Drug: Combined behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined behavioral and drug therapy (biofeedback-assisted behavioral training followed by oxybutynin chloride titrated from 2.5 mg to 15 mg daily)
Trial: 10798461
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (oxybutynin chloride)
Trial: 10798461
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug and behavioral treatment
Trial: 1305819
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 6 puffs (1500 micrograms) of terbutaline
Trial: 1305819
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 2 puffs (500 micrograms) of terbutaline at 15-minute intervals
Trial: 1305819
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 2 puffs (500 micrograms) of terbutaline at 5-minute intervals
Trial: 31939036
Drug: Intradermal botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal botulinum toxin A (50 units)
Trial: 19138360
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg once a day
Trial: 19138360
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg on alternative days
Trial: 19138360
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alfuzosin and tadalafil
Trial: 11190581
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/day (n = 12)
Trial: 9332997
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at a rate of 1 to 5 microg/kg per minute
Trial: 2877643
Drug: Beta-blockade with
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade with betaxolol (oral, cardioselective) during clinical beta-blockade (heart rate 50 to 60 beats per minute, <20% increase in heart rate over baseline during stage I treadmill exercise, Bruce protocol)
Trial: 29763434
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen 3 times a day for 3 days
Trial: 29763434
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pivmecillinam 3 times a day for 3 days
Trial: 27150261
Drug: ABT-981 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-981 (0.3, 1, 3, or 10 mg/kg intravenously; 0.3, 1, 3 mg/kg subcutaneously)
Trial: 27150261
Drug: ABT-981 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-981 (3 mg/kg subcutaneously every 4 weeks)
Trial: 27150261
Drug: ABT-981 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-981 (subcutaneous doses every 2 weeks)
Trial: 19661958
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet + 500 ml water prior to each daily meal (water group)
Trial: 19661958
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml water preload (WP)
Trial: 18598003
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg of bimosiamose
Trial: 15860254
Drug: Spironolactone (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (low doses) added to standard of care
Trial: 15860254
Drug: Eplerenone (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (selective MR antagonist)
Trial: 8694020
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g lactose (lactose-free milk)
Trial: 8694020
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g lactose
Trial: 8694020
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g lactose
Trial: 8694020
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g lactose
Trial: 29499976
Drug: 350 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 μg/week sublingual vitamin B12 (Ld)
Trial: 29499976
Drug: 2000 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 μg/week sublingual vitamin B12 (Hd)
Trial: 28093634
Drug: Oral bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisphosphonates therapy
Trial: 28093634
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of bone turnover markers (BTMs) PINP and CTX at baseline and 3 months after starting therapy
Trial: 26094080
Drug: Panitumumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (9 mg/kg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Trial: 27311415
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg calcium supplementation
Trial: 8091142
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bid (subgroup of N = 123)
Trial: 23216762
Drug: Artificial gravity
RxNorm normalized name: SPECIFIC GRAVITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial gravity (AG) exercise countermeasure (CM) group, exposed to AG for 30 min, twice daily, with ergometric exercise at 40 W intensity.
Trial: 19238653
Drug: RWJ-800088 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-800088 (doses > or = 0.75 microg/kg)
Trial: 19238653
Drug: RWJ-800088 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-800088 (doses 2.5 and 3.0 microg/kg)
Trial: 19238653
Drug: RWJ-800088 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-800088 (two highest doses)
Trial: 11003347
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks)
Trial: 11003347
Drug: i.v. ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ganciclovir (5 mg/kg q 12 hr for 7 days)
Trial: 11003347
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral prophylaxis (for patients without CMV antigenemia)
Trial: 1824
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg d-amphetamine
Trial: 23988908
Drug: Dentifrice containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing insoluble calcium compound and 1,450 ppm fluoride
Trial: 20573923
Drug: Fractional doses
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional doses of inactivated poliovirus vaccine (0.1 ml, intradermally)
Trial: 20573923
Drug: Full doses
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full doses of inactivated poliovirus vaccine (intramuscularly)
Trial: 20573923
Drug: Fractional doses
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional doses of inactivated poliovirus vaccine
Trial: 20573923
Drug: Full doses
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full doses of inactivated poliovirus vaccine
Trial: 18769864
Drug: Oral levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral levetiracetam (LEV) 500 mg twice daily
Trial: 16835214
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 150 mg daily
Trial: 14693303
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg, titrated to 160 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Trial: 14693303
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg, titrated to 10 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Trial: 10753002
Drug: Metrifonate 30-60
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 30-60 mg
Trial: 6357936
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg, acute administration)
Trial: 6357936
Drug: Propranolol (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (chronic administration, dosage reducing heart rate by 25%)
Trial: 6357936
Drug: Propranolol (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (acute and chronic administration)
Trial: 26626336
Drug: Training group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training group (n=10) performing barbell back squats and deadlifts twice per week for four weeks
Trial: 19903658
Drug: AA plus
RxNorm normalized name: Homactin AA plus 20PE Suspension (Berry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA plus G (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%)
Trial: 17699390
Drug: G only
RxNorm normalized name: Selexipag only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G only (control dialysate)
Trial: 18572233
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity (PA) intervention with bupropion and nicotine patch, including a pedometer, counseling to increase steps by 10% biweekly towards a 10,000 steps/day goal, and personalized reports for 40 weeks.
Trial: 18572233
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity (PA) intervention with bupropion and nicotine patch.
Trial: 9532686
Drug: Hep-A-in-Vac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hep-A-in-Vac vaccine
Trial: 7976448
Drug: Medication-free clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free clinical treatment
Trial: 31022252
Drug: Preventive treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatments for RA (e.g., non-biologic drugs like hydroxychloroquine, atorvastatin, biologics)
Trial: 31022252
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment vs. infusion
Trial: 30573748
Drug: Licensed trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed trivalent influenza vaccine
Trial: 30573748
Drug: Novel virus-like
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel virus-like particle based vaccine
Trial: 26986471
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (ISTp) with dihydroartemisinin-piperaquine (DP)
Trial: 26986471
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP)
Trial: 26986471
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Trial: 25210017
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral lenalidomide (20 mg/day)
Trial: 19050386
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg intravenous)
Trial: 11600352
Drug: Reference capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference capsule formulation of amoxicillin
Trial: 11600352
Drug: Test capsule
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test capsule formulation of amoxicillin
Trial: 11600352
Drug: Reference and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference and test suspensions of amoxicillin
Trial: 11600352
Drug: Various amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various amoxicillin formulations (250 to 1,000 mg)
Trial: 11600352
Drug: Two-point LSS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-point LSS models for T>MICs of 0.25 or 2.0 microg/ml
Trial: 3120487
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg selegiline (1‐deprenyl)
Trial: 3120487
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Madopar + 10 mg selegiline (1‐deprenyl)
Trial: 3120487
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Madopar + placebo
Trial: 23575810
Drug: Vigabatrin (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (3.0 g/d)
Trial: 19912207
Drug: Tolterodine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine combined with behavioral therapies including individualized fluid management instructions
Trial: 16316699
Drug: Coronary risk
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary risk factors and inflammation assessment in CAD patients with ICD implants
Trial: 8993956
Drug: Homoeopathic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathic therapy (n = 30)
Trial: 8993956
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (n = 30)
Trial: 7703597
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition (IVN) for 10 days
Trial: 18424600
Drug: Full-dose muffins
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose muffins (control)
Trial: 17587720
Drug: Amiodarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (400 mg/day) 2 months before PTMV
Trial: 17587720
Drug: Amiodarone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (200 mg/day) after cardioversion
Trial: 9579811
Drug: PGI/MN II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGI/MN II monoclonal antibodies
Trial: 9579811
Drug: D8/17 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D8/17 monoclonal antibodies
Trial: 7607786
Drug: 5-ASA at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA at 2.4 g/day in a delayed-release formulation (Eudragit-S-coated Mesaline)
Trial: 7607786
Drug: Non-specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific therapy (Control group)
Trial: 10919899
Drug: Valaciclovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (500 mg, three times daily)
Trial: 10919899
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg, five times daily)
Trial: 1451073
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy (AHRT) at 48.0 Gy
Trial: 1451073
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy (AHRT) at 54.4 Gy
Trial: 1451073
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy (RT) and bis-chloroethyl nitrosourea (BCNU) for patients 60 years or older
Trial: 30591391
Drug: Photobiomodulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation with low-level laser therapy (LLLT)
Trial: 29464587
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day vonoprazan